Joseph Geradts
Overview
Explore the profile of Joseph Geradts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
5274
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Manescu P, Geradts J, Fernandez-Reyes D
Am J Pathol
. 2024 Dec;
PMID: 39732389
Understanding the tumor hypoxic microenvironment is crucial for grasping tumor biology, clinical progression, and treatment responses. This study presents a novel application of artificial intelligence in computational histopathology to evaluate...
2.
Van Berckelaer C, Van Laere S, Lee S, Morse M, Geradts J, Dirix L, et al.
Transl Oncol
. 2024 Feb;
43:101907.
PMID: 38412664
Objective: To assess the expression pattern of X-linked inhibitor of apoptosis protein (XIAP), a cellular stress sensor, and delineate the associated changes in the tumor immune microenvironment (TiME) for prognostic...
3.
Kim W, Buckley A, Lee D, Hiroto A, Nenninger C, Olson A, et al.
Nat Commun
. 2024 Feb;
15(1):1231.
PMID: 38336745
Androgen deprivation therapy (ADT) targeting androgen/androgen receptor (AR)- signaling pathways is the main therapy for advanced prostate cancer (PCa). However, ADT eventually fails in most patients who consequently develop castration-resistant...
4.
Shi Y, Olsson L, Hoadley K, Calhoun B, Marron J, Geradts J, et al.
NPJ Breast Cancer
. 2023 Nov;
9(1):92.
PMID: 37952058
Approaches for rapidly identifying patients at high risk of early breast cancer recurrence are needed. Image-based methods for prescreening hematoxylin and eosin (H&E) stained tumor slides could offer temporal and...
5.
Ryser M, Greenwald M, Sorribes I, King L, Hall A, Geradts J, et al.
bioRxiv
. 2023 Oct;
PMID: 37873488
Ductal carcinoma in situ (DCIS) and invasive breast cancer share many morphologic, proteomic, and genomic alterations. Yet in contrast to invasive cancer, many DCIS tumors do not progress and may...
6.
Mohamed A, Olsson L, Geradts J
Breast Cancer Res Treat
. 2023 Jul;
201(3):447-460.
PMID: 37453958
Purpose: The Oncotype DX Recurrence Score (RS) is a widely used prognostic tool for estrogen receptor-positive breast cancer patients. Multiple surrogate models can predict RS with good accuracy. In this...
7.
Hurson A, Hamilton A, Olsson L, Kirk E, Sherman M, Calhoun B, et al.
Breast Cancer Res Treat
. 2023 Mar;
199(1):147-154.
PMID: 36892725
Background: The PAM50 assay is used routinely in clinical practice to determine breast cancer prognosis and management; however, research assessing how technical variation and intratumoral heterogeneity contribute to misclassification and...
8.
Hiroto A, Kim W, Pineda A, He Y, Lee D, Le V, et al.
Nat Commun
. 2022 Nov;
13(1):6552.
PMID: 36323713
The androgen receptor (AR)-signaling pathways are essential for prostate tumorigenesis. Although significant effort has been devoted to directly targeting AR-expressing tumor cells, these therapies failed in most prostate cancer patients....
9.
Rebbeck C, Xian J, Bornelov S, Geradts J, Hobeika A, Geiger H, et al.
Nat Commun
. 2022 Jun;
13(1):3399.
PMID: 35697697
Ductal carcinoma in situ (DCIS) is considered a non-invasive precursor to breast cancer, and although associated with an increased risk of developing invasive disease, many women with DCIS will never...
10.
Carmichael I, Calhoun B, Hoadley K, Troester M, Geradts J, Couture H, et al.
Ann Appl Stat
. 2022 Apr;
15(4):1697-1722.
PMID: 35432688
The two main approaches in the study of breast cancer are histopathology (analyzing visual characteristics of tumors) and genomics. While both histopathology and genomics are fundamental to cancer research, the...